A Case of Hypokalemia with Synthetic Cannabinoid Use

Synthetic cannabinoids cause a variety of central nervous symptoms, tachycardia and hypokalemia. We report a 27 old male patient was admitted to emergency room due to altered consciousness and vomiting. The patient declared that he smoked herbal incense named Bonzai. After a few hours he was found by his friends with impaired consciousness, no verbal response, and tonic seizure of upper extremities. He vomited once and denied intractable vomiting and diarrhea. His past medical history was nonsignificant and he was not taking any prescription drugs. Potassium (K+) and ethanol concentration was low at the time of admission (2.7 meq/l and 18 mg/dl, respectively). After infusion of 60 meq potassium chloride (KCl), repeat K+ value was 3.5 meq/l. Twenty four hours after admission K+ level dropped to 3.2 meq/l. Potassium level reached to normal value (5 meq/l) after 40 meq KCL infusion. He was discharged uneventfully. Hypokalemia due to synthetic cannabinoid usage may be due to a number of mechanisms including potassium loss via kidneys, potassium loss due to excessive sweating and diarrhea, and potassium shift into cells. Although our patient vomitted once, gastrointestinal loss may not be the sole explanation to hypokalemia. It must be kept in mind that there may be causes of hypokalemia other than vomiting in setting of synthetic cannabinoid use.

PDF

___

1. Pierre JM. Cannabis, synthetic cannabinoids, and psychosis risk: what the evidence says. Curr Psychiatr. 2011;10(9):49-58.

2. Gurdal F, Asirdizer M, Aker RG, Korkut S, Gocer Y, Kucukibrahimoglu EE, Ince CH. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. J Forensic Leg Med. 2013;20(6):667-72.

3. Wende M, Schäper J. Qualitative and quantitative analysis of synthetic cannabinoids in smoking mixtures of the "Spice" type using LC-MS/MS. Toxichem Krimtech 2011;78(2):297-301.

4. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108(3):534-44.

5. Vearrier D, Osterhoudt KC. A teenager with agitation: higher than she should have climbed. Pediatr Emerg Care. 2010;26(6):462-5.

6. Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clin J Am Soc Nephrol. 2013;8(4):523-6.

7. Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(6):93-8.

8. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153(2):263-70.

9. Larrinaga G, Varona A, Pérez I, Sanz B, Ugalde A, Cándenas ML, Pinto FM, Gil J, López JI. Expression of cannabinoid receptors in human kidney. Histol Histopathol. 2010;25(9):1133-8.

10. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB? and CB?. Pharmacol Rev. 2010;62(4):588-631.

11. Wells DL, Ott CA. The "new" marijuana. Ann Pharmacother. 2011;45(3):414-7